GoodRx’s Post

#HbA1c_Testing Market Report: Detailed Demand Analysis, Statistics, Industry Trends And Investment Opportunities To 2032 >> https://lnkd.in/eyvQwzxz #Hemoglobin A1C is mostly abbreviated as #HbA1c, it is a form of hemoglobin (a blood #pigment that carries blood) which is bound to #glucose. This test is basically carried out in people with type 1 and type 2 diabetes. The level HBA1c shows how well #diabetes is controlled in the individual. The normal range for HBA1c is less than 6%. They are also known as glycosylated, or glycated hemoglobin. Abbott Alere Inc. ARKRAY,Inc. Bio-Rad Laboratories Danaher Corporation Wohlfahrtsstiftung der F. Hoffmann-La Roche AG Siemens Healthcare FZ LLC Transasia Bio-Medicals Ltd. Trinity Biotech #medicaldevices #hbA1ctesting #hemoglobin #glucose #diabetes #healthcareindustry #pharmaceuticalindustry 

𝐀𝐧𝐚𝐥 𝐅𝐢𝐬𝐬𝐮𝐫𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 2032/ Global Insight Services The global Anal Fissure Treatment Market size was approximately USD 1.3 billion in 2022 and it is anticipated to grow up to nearly USD 2.75 billion by 2032, at a CAGR of 7.7% during the forecast period. An anal fissure is a small tear or cut in the lining of the anus, often causing pain and discomfort during bowel movements. Treatment for anal fissures typically involves non-surgical approaches as a first line of defense. This may include dietary modifications to soften stools, increased fiber intake, and the use of stool softeners to alleviate strain during bowel movements. Topical medications, such as nitroglycerin ointment, may be prescribed to relax the anal sphincter muscles and promote healing. Visit the following page to request free sample pages https://lnkd.in/euqbs37Y #analfissure #laxatives #healthcare #treatment #bowelcare #healing #medicines 𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 Novartis Teva Pharmaceuticals Troikaa Pharmaceuticals Ltd. Kyowa Kirin, Inc.- U.S. Kyowa Kirin, Inc.- U.S. Cipla Ipsen Sanofi Boehringer Ingelheim Bliss GVS Pharma Ltd.

Vildagliptin IP tablets, branded as Galvus 50mg, are highly effective for managing type 2 diabetes. They help regulate blood sugar levels by inhibiting the DPP-4 enzyme, which increases insulin production and decreases glucose production in the liver. This ensures better glycemic control, reduces HbA1c levels, and enhances overall health. Ideal for patients seeking effective and reliable diabetes management. #DiabetesCare #BloodSugarControl #Galvus50mg #Type2Diabetes #HealthyLiving #Vildagliptin #GlycemicControl #JaiswalPharma #PharmaBag #WholesaleMedicine #PharmaWholesale #MedicineDistributor #HealthcareSupplyChain #PharmaLogistics #PharmacyWholesale #MedicalSupplies #DrugDistribution #HealthcareDistributor #PharmaSuppliers #PharmaceuticalSuppliers #MedSupplyChain #Biocon #Glenmark #PharmaBusiness #DrugWholesale #SunPharma #Cipla #DrReddys #LupinPharma #AurobindoPharma #NovartisIndiaLtd #Valdast-m

The Levothyroxine Sodium market is poised for growth, with a value of $3.73 billion in 2023, projected to reach $3.90 billion in 2024 at a 4.4% CAGR. By 2028, it is expected to hit $4.65 billion. Key growth drivers include heightened awareness of hypothyroidism, expanded insurance coverage, and the introduction of cost-effective generics. Innovations like gel capsules, such as IBSA Pharma's Tirosint launched in 2023, are enhancing patient care. North America leads the market, while Asia-Pacific is set to grow rapidly due to rising healthcare investments. For more Info: https://lnkd.in/gH_BCZJ9 #HealthcareInnovation #Pharmaceuticals #ThyroidHealth #Levothyroxine #MarketGrowth #HealthCare #tbrc

The global diabetes drug market is projected to grow from $70.4 billion in 2024 to over $132 billion by 2034, with significant expansion in key segments like insulin and oral treatments. 👉🏼 Swipe through the infographics below for key insights into this fast-growing market! This growth underscores the increasing demand for effective solutions for diabetes management. Farmaprojects portfolio includes generic drugs tailored to diabetes care. Browse through our product list: https://lnkd.in/ds2kuV93 #Diabetes #Healthcare

Weight-Loss Drug is Set to Become a $77B Market by 2030, a 413% Increase in Market Share From 2024. A key part of this is the broadening utility of these medicines. After all, #semaglutide, the key ingredient in drugs like #Ozempic, #WeGovy and #Rybelsus was initially developed for diabetes management. Its appetite suppressant abilities put it on the weight-loss market. But weight management also lowers the risk of heart attacks and strokes, it could be prescribed for many related issues. Source: Visual Capitalist

As #diabetes and #obesity rates continue to rise globally, the demand for GLP-1 drugs is expected to surge. #GLP-1 drugs work by mimicking hormones released in the gastrointestinal tract in response to eating, and stimulate insulin production (reducing blood glucose), and interact with the brain to reduce appetite and to more quickly signal a feeling of satiety. While GLP-1 drugs date back to 2005 as targeted treatments for Type 2 diabetes, interest in GLP-1 has skyrocketed having shown clear efficacy in #weightmanagement and FDA approval for obesity. The strong preliminary evidence of cardiovascular benefits (including a ~20% reduction in #heartattack and stroke) and other possible use cases has further boosted perceptions of the enormous addressable market opportunity. As a result, global GLP-1 sales, around $40bn in 2023, could approach $150bn by 2032 (15.8% CAGR), with Novo Nordisk and Eli Lilly together comprising close to 100% of the market for now (competitive entrants are assumed to take up to 15% share by 2032). Clearly, this is a potential massive game-changer in the obesity crisis we have in the US but my questions are A) Will this be a miracle extensive fix for all by itself? and B) If it needs supplementary effort to keep the weight off (with #exercise, good #nutrition etc). What should entrepreneurs and intrapreneurs be thinking about to render better #innovation and #technology here (& #digitalhealth and #virtualcare tools in particular? Thoughts appreciated! #Entrepreneurship #pyschology #healthtechnology #growthmindset #populationhealth #healtheconomics https://lnkd.in/gcfahCdz

India's Diabetes & Obesity Drug Market Sees Boom🕺 💰Sales Surge: A new oral medication targeting both diabetes and obesity has witnessed a 100% sales increase in India year-on-year (data from April 2023 to April 2024). 💊The Drug: Novo Nordisk's Rybelsus (semaglutide) is a major player, offering an oral alternative for type 2 diabetes management and weight reduction. 🚀Market Growth: This surge reflects a broader trend. India's anti-obesity drug market has tripled in the past two years, with semaglutide holding a dominant market share. 📈 Underlying Trend: This growth is likely driven by India's rising obesity rates, prompting increased demand for weight management solutions alongside diabetes treatment. #healthcare #diabetes #obesity #weightloss #pharmaceutical #India

Insulin glargine is a long-acting synthetic insulin used to control blood sugar in adults, adolescents, and children aged 2 and older. It promotes glucose uptake in tissues like muscles and fat while reducing glucose production in the liver. By regulating glucose metabolism and inhibiting fat breakdown, insulin glargine helps manage blood sugar levels effectively in people with diabetes.   Veeda Group, with over a decade of experience in supporting Type 1 and Type 2 diabetes management, conducted a study for an Indian pharmaceutical company seeking marketing approval for Insulin Glargine 100 U/mL. The study aimed to demonstrate the equivalence of the pharmacokinetic and pharmacodynamic properties of Insulin Glargine 100 U/mL in healthy adult male subjects under fasting conditions and also assessed the safety and tolerability of subjects after a single-dose administration of both the test and reference products   To learn more on Insulin Glargine: A long-acting solution for Type 1 & Type 2 Diabetes Management, visit https://bit.ly/3LWbMZy   To know more write to us at info@veedacr.com or visit at www.veedacr.com Partners in creating a healthier tomorrow. #Veeda #VeedaCR #VeedaClinicalResearch #DrugDevelopment #InsulinGlargine #Insulin #DiabetesManagement #Casestudy

While GLP-1 medications like Wegovy and Zepbound are highly effective tools for weight loss, they raise an important consideration: muscle preservation. Weight loss at the expense of lean muscle can lead to future challenges, including reduced basal metabolic rate, decreased strength, lower bone density, and increased risk of weight recurrence. I recently spoke with Medical News Today about the link between GLP-1 medications and muscle loss, who is most at risk, and the strategies to preserve muscle mass. "The key to healthy, sustainable weight loss is maintaining protein intake and nutrition, performing regular resistance exercise, and staying consistent." For anyone on a GLP-1, integrating strength training, prioritizing protein, and consistency are non-negotiables for long-term success. https://lnkd.in/gtPJANTE